ANTH (Anthera Pharmaceuticals) EV-to-OCF: -0.00 (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Anthera Pharmaceuticals EV-to-OCF?

Anthera Pharmaceuticals ANTH EV-to-OCF is -0.00 as of Aug. 22, 2026.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Anthera Pharmaceuticals's Enterprise Value is $0.00 Mil. Anthera Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2018 was $-31.95 Mil. Therefore, Anthera Pharmaceuticals's EV-to-OCF for today is -0.00.

The historical rank and industry rank for Anthera Pharmaceuticals's EV-to-OCF or its related term are showing as below:

ANTH's EV-to-OCF is not ranked *
in the Biotechnology industry.
Industry Median: -3.61
* Ranked among companies with meaningful EV-to-OCF only.

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-22), Anthera Pharmaceuticals's stock price is $0.0001. Anthera Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2018 was $-1.700. Therefore, Anthera Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

Anthera Pharmaceuticals  (OTCPK:ANTH) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Anthera Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-1.700
=At Loss

Anthera Pharmaceuticals's share price for today is $0.0001.
Anthera Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.700.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Anthera Pharmaceuticals EV-to-OCF Related Terms

Anthera Pharmaceuticals EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Anthera Pharmaceuticals's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthera Pharmaceuticals EV-to-OCF Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.61 -1.32 -4.49 -0.36 -0.57

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANTH vs TIKRF, CAPS, AKAOQ: EV-to-OCF Comparison

For the Biotechnology subindustry, Anthera Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anthera Pharmaceuticals EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's EV-to-OCF falls into.


Anthera Pharmaceuticals EV-to-OCF Calculation

Anthera Pharmaceuticals's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=0.003/-31.952
=-0.00

Anthera Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Anthera Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of -0.00 mean?
Anthera Pharmaceuticals (ANTH) has a EV-to-OCF of -0.00 as of Aug. 22, 2026.
Is Anthera Pharmaceuticals' EV-to-OCF too high?
Anthera Pharmaceuticals' current EV-to-OCF is -0.00.
How does Anthera Pharmaceuticals' EV-to-OCF compare to TIKRF and CAPS?
Anthera Pharmaceuticals' EV-to-OCF of -0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Anthera Pharmaceuticals's current EV-to-OCF is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthera Pharmaceuticals stock overvalued right now?
Anthera Pharmaceuticals (ANTH) has a current EV-to-OCF of -0.00. The current EV-to-OCF is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Anthera Pharmaceuticals (ANTH), the current EV-to-OCF is -0.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthera Pharmaceuticals Business Description

Address 700 Milam, Suite 1300, Houston, TX, USA, 77002
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.